{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-24-000062","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.358065+00:00","generated_at":"2026-06-02T12:32:14.396211+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M","bullets":["Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).","Net loss of $35.7M ($1.01 loss per share) vs $23.4M loss in Q1 2023.","SG&A expenses surged to $51.6M from $15.1M due to commercial launch costs.","Cash and marketable securities $298.5M as of Mar 31; secured $200M credit facility in Apr 2024 (drew $75M).","Secured commercial payer contracts covering ~18M lives on preferred status; broad coverage expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-24-000062","json":"https://secwatch.observer/filing/0001819790-24-000062.json","markdown":"https://secwatch.observer/filing/0001819790-24-000062.md","text":"https://secwatch.observer/filing/0001819790-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/0001819790-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/tars-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:32:14.396211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f4fd4638919d9630b43be4dfca74ca1ba070da6","claim":"Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $27.6 million, net income $35.7 million, EPS $(1.01).","evidence_excerpt":"million at the close, providing approximately $40 million net after the repayment of the previous facility First Quarter 2024 Financial Results • First quarter revenues were $27.6 million, driven primarily by $24.7 million in net product sales, and $2.9 million in license fees and collaboration revenue. • Cost of sales were $1.7 million, due to manufacturing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/0001819790-24-000062-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$27.6 million"},{"label":"Net income","value":"$35.7 million"},{"label":"EPS","value":"$(1.01)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}